Table 1.
The basic characteristics of the thirteen included studies in the systematic review.
| Studies (year) | Country | Study design | Reference standard | No. of P (M and S)/C | Age (years) | Gestational week at sampling | MPV value (fl) | TP | FP | TN | FN | Cut-off | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-eclampsia group | Control group | Pre-eclampsia group | Control group | Pre-eclampsia group | Control group | ||||||||||
| Liu 2022 (34) | China | Retro | Guidelinea | 60/60 | 29.58 ± 5.06b | 28.28 ± 5.20 | 12.46 ± 1.19 | 12.57 ± 0.68 | 9.54 ± 1.13 | 8.87 ± 0.95 | 54 | 37 | 23 | 6 | 8.545 |
| Walle 2022 (35) | Ethiopia | NR | ACOG | 63/63 | 28.1 ± 4.61 | 27.5 ± 4.77 | 34.1 ± 4.4 | 33.8 ± 4.8 | 13.47 ± 1.43 | 11.27 ± 0.92 | 53 | 8 | 55 | 10 | ≥12.10 |
| Oğlak 2021 (36) | Turkey | Retro | ACOG | 201 (94 and 107)/100 | M: 28.3 ± 7.4; S: 28.7 ± 6.8 | 27.4 ± 6.1 | M: 7.2 ± 1.1; S: 7.4 ± 1.3 | 7.4 ± 1.2 | M: 10.6 ± 2.3; S: 11.2 ± 1.4 | 10.3 ± 1.3 | 128 | 35 | 65 | 73 | 10.65 |
| Li 2021 (37) | China | NR | Unclearc | 92 (54 and 38)/178 | 32.0 (28.0–31.0)d | 31.0 (27.0–34.0) | 20–24 weeks | M: 10.7 (9.6–11.3); S: 11.8 (9.9–13.5) | 9.2 (8.0–10.7) | 77 | 25 | 153 | 15 | 10.5 | |
| Yang 2021 (38) | China | NR | Obstetrics and gynecology | 162/113 | 29.93 ± 5.7 | 29.23 ± 4.68 | 34.1 ± 4.4 | 33.8 ± 4.8 | 10.50 (9.48–11.40)d | 9.90 (9.40–10.75) | 68 | 24 | 89 | 94 | 10.85 |
| Wang 2021 (39) | China | Retro | Obstetrics and gynecology | 100 (40 and 60)/50 | M: 28.38 ± 1.2; S: 28.41 ± 1.23 | 28.12 ± 1.3 | M: 38.61 ± 1.0; S: 38.59 ± 1.03 | 31.45 ± 1.4 | M: 9.75 ± 1.04; S: 10.34 ± 1.1 | 8.69 ± 0.2 | 13 | 5 | 45 | 87 | 9.35 |
| Bhamri 2019 (40) | India | Prosp | ACOG | 83 (61 and 22)/333 | 26.43 ± 3.47 | 25.71 ± 2.64 | 11–14 weeks | 11.41 ± 1.57 | 10.71 ± 1.81 | 57 | 147 | 186 | 26 | >10.550 | |
| Tesfay 2019 (41) | Ethiopia | NR | Unclearc | 79 (35 and 44)/140 | M: 25.20 ± 3.5; S: 25.64 ± 5.26 | 25.64 ± 3.9 | M: 34.51 ± 4.48; S: 34.61 ± 3.99 | 35.99 ± 3.58 | M: 11.5 ± 2.1; S: 12.3 ± 1.7 | 8.4 ± 0.9 | 66 | 19 | 121 | 13 | >9.45 |
| Wang 2019 (42) | China | Retro | Obstetrics and gynecology | 91 (34 and 57)/54 | 29.1 ± 3.0 | 26.7 ± 4.3 | Antepartum | 10.8 ± 1.3 | 9.6 ± 0.9 | 62 | 7 | 47 | 29 | 10.35 | |
| Kim 2018 (27) | Korea | Retro | ACOG | 353 (126 and 227)/471 | M: 32.8 ± 4.6; S: 32.9 ± 4.3 | 33.3 ± 4.1 | M: 36.1 ± 3.6; S: 33.2 ± 3.7 | 38.7 ± 1.0 | M: 9.5 ± 0.1; S: 9.8 ± 0.1 | 8.8 ± 0.07 | 131 | 92 | 379 | 222 | 9 |
| Rezk 2018 (43) | Egypt | Prosp | Unclearc | 286/9236 | 30.9 ± 9.9 | 31.2 ± 9.8 | 18–20 weeks | 9.89 ± 0.8 | 8.51 ± 0.85 | 272 | 3076 | 6160 | 14 | 9.55 | |
| Chen 2017 (44) | China | Retro | ACOG | 125/188 | 29.06 ± 4.36 | 28.87 ± 3.98 | 27–41 weeks | 10.40 ± 2.63 | 9.49 ± 1.35 | 96 | 66 | 122 | 29 | >10 | |
| Mannaerts 2017 (45) | Belgium | Retro | ACOG | 118/1495 | 28.91 ± 4.91 | 30.20 ± 5.19 | Before 20 weeks | 8.06 ± 0.87 | 8.64 ± 1.17 | 79 | 653 | 842 | 39 | 8.15 | |
| 59/138 | 28.03 ± 5.06 | 31.96 ± 4.50 | Antepartum | 9.51 ± 1.21 | 8.90 ± 1.17 | 41 | 69 | 69 | 18 | 8.85 | |||||
| Gezer 2016 (46) | Türkiye | Retro | ACOG | 137/150 | 28.3 ± 5.98 | 27.5 ± 5.01 | 7–14 weeks | 8.38 ± 1.12 | 9.02 ± 1.08 | 86 | 53 | 97 | 51 | 8.6 | |
| Emel Kurtoglu 2016 (47) | Türkiye | Retro | ACOG | 150 (29 and 121)/100 | 28.9 ± 7.0 | 30.4 ± 5.3 | 25–41 weeks | 9.0 (5.9–14.2)e | 8.3 (5.9–12.1) | 102 | 48 | 52 | 48 | 8.35 | |
| Nooh 2015 (48) | Egypt | NR | ACOG | 192/2621 | NR | NR | 24–28 weeks | NR | NR | 178 | 341 | 2280 | 14 | >9.5 | |
| Han 2014 (49) | China | Retro | ACOG | 94 (53 and 41)/79 | M: 27.2 ± 1.9; S: 27.5 ± 1.6 | 26.7 ± 2.3 | M: 80.5 ± 3.2; S: 78.4 ± 2.8f | 81.7 ± 3.5 | NR | NR | 87 | 62 | 17 | 7 | 8.95 |
| Kanat-Pektas 2014 (50) | Türkiye | Prosp | ACOG | 15/164 | 25.2 ± 4.1 | 26.2 ± 5.3 | 12.6 ± 0.7 | 12.6 ± 0.8 | 11.0 ± 1.2 | 10.2 ± 0.9 | 10 | 59 | 105 | 5 | 10.5 |
| Kashanian 2013 (51) | Iran | Prosp | Unclearc | 35/269 | 27.7 ± 6.1 | 26.9 ± 5.4 | 10.5 ± 1 | 10.6 ± 1.2 | 10.2 ± 1.06 | 9.68 ± 1.09 | 21 | 54 | 215 | 14 | 11.1 |
| 26–28 weeks | 10.16 ± 1.23 | 9.62 ± 1.12 | 20 | 49 | 220 | 15 | 10.5 | ||||||||
| Dundar 2008 (52) | Türkiye | NR | ISSHP | 107/1229 | 28.3 ± 4.3 | 27.2 ± 6.1 | 24–28 weeks | NR | NR | 83 | 172 | 1057 | 24 | >8.5 | |
NR, no report; No. of P (M and S)/C, number of pre-eclampsia patients (mild pre-eclampsia/severe pre-eclampsia)/control; Prosp, prospective; Retro, retrospective; M, mild pre-eclampsia; S, severe pre-eclampsia; FN, false negative; FP, false positive; TN, true negative; TP, true positive.
a
Guidelines for Diagnosis and Treatment of Hypertensive Diseases during Pregnancy (2020).
b
Mean ± standard deviation.
c
Unclear: clinical diagnostic criteria were used, but the names of the criteria were not specified.
d
Medians (quartiles).
e
Median (min–max).
f
Early pregnancy test day.